Developments in identifying and managing mucormycosis in hematologic cancer patients

References

• Pagano L, Ricci P, Tonso A, et al. Mucormycosis in patients with haematological malignancies: a retrospective clinical study of 37 cases. GIMEMA infection program (Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto). Br J Haematol. 1997;99:331–336.
   PubMed Web of Science ®Google Scholar
• Pagano L, Offidani M, Fianchi L, et al. Mucormycosis in hematologic patients. Haematologica. 2004;89:207–214.
   PubMed Web of Science ®Google Scholar
• Marty FM, Ostrosky-Zeichner L, Cornely OA, et al. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. Lancet Infect Dis. 2016;16:828–837.
   PubMed Web of Science ®Google Scholar
• Greenberg RN, Mullane K, van Burik JA, et al. Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother. 2006;50:126–133.
   Google Scholar
• Skiada A, Lass-Floerl C, Klimko N, et al. Challenges in the diagnosis and treatment of mucormycosis. Med Mycol. 2018;56:S93–S101.
   PubMed Web of Science ®Google Scholar
• Chakrabarti A, Singh R. Mucormycosis in India: unique features. Mycoses. 2014;57:85–90.
   PubMed Web of Science ®Google Scholar
• Prakash H, Chakrabarti A. Global epidemiology of mucormycosis. J Fungi. 2019;5(1):26.
   Web of Science ®Google Scholar
• Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis. A review of 929 reported cases. Clin Infect Dis. 2005;41(5):634–653.
   PubMed Web of Science ®Google Scholar
• Ruping MJGT, Heinz WJ, Kindo AJ, et al. Forty-one recent cases of invasive zygomycosis from a global clinical registry. J Antimicrob Chemother. 2009;65(2):296–302.
   PubMed Web of Science ®Google Scholar
• Xhaard A, Lanternier F, Porcher R, et al. Mucormycosis after allogeneic haematopoietic stem cell transplantation: a French multicentre cohort study (2003-2008). Clin Microbiol Infect. 2012;18(10):E396–E400.
   PubMed Web of Science ®Google Scholar
• Guinea J, Escribano P, Vena A, et al. Increasing incidence of mucormycosis in a large Spanish hospital from 2007 to 2015: epidemiology and microbiological characterization of the isolates. PLoS One. 2017;15(2):e0229347.
   PubMed Web of Science ®Google Scholar
• Lien M-Y, Chou C-H, Lin C-C, et al. Epidemiology and risk factors for invasive fungal infections during induction chemotherapy for newly diagnosed acute myeloid leukemia: A retrospective cohort study. PLoS One. 2018;13(6):e0197851.
   Web of Science ®Google Scholar
• M S L, R E L, Kontoyiannis DP. Breakthrough invasive mold infections in the hematology patient: current concepts and future directions. Clin Infect Dis. 1621-1630;67(10):2018.
   Google Scholar
• Jeong W, Keighley C, Wolfe R, et al. The epidemiology and clinical manifestations of mucormycosis: a systematic review and meta-analysis of case reports. Clin Microbiol Infect. 2019;25(1):26–34.
   PubMed Web of Science ®Google Scholar
• Zarei M, Morris J, Aachi V, et al. Acute isolated cerebral mucormycosis in a patient with high grade non-Hodgkin lymphoma. Eur J Neurol. 2000;7(4):443–447.
   PubMed Web of Science ®Google Scholar
• Tisi MC, Giustiniani MC, D’alò F, et al. A T cell lymphoblastic lymphoma with mucormycosis as unusual etiology of acute cerebral ischemia. Ann Hematol. 2016;95(3):517–518.
   PubMed Web of Science ®Google Scholar
• Aftandilian C, Eguiguren L, Mathew R, et al. Mucormycosis diagnosed during induction chemotherapy in five pediatric patients with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2019;66(9):e27834.
   PubMed Web of Science ®Google Scholar
• Beketova TR, Bailey L, Crowell EL, et al. Orbitocerebral mucormycosis in a patient with central nervous system lymphoma. Ophthalmic Plast Reconstr Surg. 2018;34(6):e197–e201.
   PubMed Web of Science ®Google Scholar
• Abdelwahab Hassan MI, Voigt K. Pathogenicity patterns of mucormycosis: epidemiology, interaction with immune cells and virulence factors. Med Mycol. 2019;57(2):S245–S256.
   PubMedGoogle Scholar
• Klimko N, Khostelidi S, Shadrivova O, et al. Contrasts between mucormycosis and aspergillosis in oncohematological patients. Med Mycol. 2019;57:S138–S144.
   PubMed Web of Science ®Google Scholar
• Cornely OA, Alastruey-Izquierdo A, Arenz D, et al. Global guidelines for the diagnosis and management of mucormycosis: an initiative of the European confederation of medical mycology in cooperation with mycoses study group education and research consortium. Lancet Infect Dis. 2019;19(12):405–421.
   PubMed Web of Science ®Google Scholar
• Lanternier F, Dannaoui E, Morizot G, et al. A global analysis of mucormycosis in France: the RetroZygo study (2005-2007). Clin Infect Dis. 2012;54:35–43.
   PubMed Web of Science ®Google Scholar
• Cornu M, Sendid B, Mery A, et al. Evaluation of mass spectrometry-based detection of panfungal serum disaccharide for diagnosis of invasive fungal infections: results from a collaborative study involving six European clinical centers. J Clin Microbiol. 2019;58(1):e01755–19.
   Web of Science ®Google Scholar
• Kanako S, Ken-Ichi O, Mamiko N, et al. Identification of a novel rhizopus-specific antigen by screening with a signal sequence trap and evaluation as a possible diagnostic marker of mucormycosis. Med Mycol. 2017;55(7):713–719.
   PubMed Web of Science ®Google Scholar
• Potenza L, Vallerini D, Barozzi P, et al. Specific T cells in patients with hematologic malignancies. PLoS One. 2016;11(2):e0149108.
   PubMed Web of Science ®Google Scholar
• Skiada A, Lanternier F, Groll AH, et al. Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3). Haematologica. 2013;98(4):492–504.
   PubMed Web of Science ®Google Scholar
• Yan Y, Zhao Z, Dong G, et al. Using IFN-γ antibodies to identify the pathogens of fungal rhinosinusitis: A novel immunohistochemical approach. Mol Med Rep. 2018;17(3):3627–3632.
   PubMed Web of Science ®Google Scholar
• Montone K, Livolsi V, Lanza D, et al. MPH, in situ hybridization for specific fungal organisms in acute invasive fungal rhinosinusitis. Am J Clin Pathol. 2011;135(2):190–199.
   PubMed Web of Science ®Google Scholar
• Walther G, Pawłowska J, Alastruey-Izquierdo A, et al. DNA barcoding in Mucorales: an inventory of biodiversity. Persoonia. 2013;30:11–47.
   PubMed Web of Science ®Google Scholar
• Chowdhary A, Singh PK, Kathuria S, et al. Comparison of the EUCAST and CLSI broth microdilution methods for testing isavuconazole, posaconazole, and amphotericin B against molecularly identified mucorales species. Antimicrob Agents Chemother. 2015;59(12):7882–7887.
   PubMed Web of Science ®Google Scholar
• Caramalho R, Maurer E, Binder U, et al. Etest cannot be recommended for in vitro susceptibility testing of Mucorales. Antimicrob Agents Chemother. 2015;59(6):3663––3665.
   Web of Science ®Google Scholar
• Millon L, Scherer E, Rocchi S, et al. Molecular strategies to diagnose mucormycosis. J Fungi. 2019;MDPI 5(1):24.
   Web of Science ®Google Scholar
• Bialek R, Konrad F, Kern J, et al. PCR based identification and discrimination of agents of mucormycosis and aspergillosis in paraffin wax embedded tissue. J Clin Pathol. 2005;58(11):1180–1184.
   PubMed Web of Science ®Google Scholar
• Bernal-Martínez L, Buitrago MJ, Castelli MV, et al. Development of a single tube multiplex real-time PCR to detect the most clinically relevant Mucormycetes species. Clin Microbiol Infect. 2013;19(1):E1–E7.
   PubMed Web of Science ®Google Scholar
• Hata DJ, Buckwalter SP, Pritt BS, et al. Real-Time PCR Method for Detection of Zygomycetes. J Clin Microbiol. 2008;46(7):2353–2358.
   PubMed Web of Science ®Google Scholar
• Springer J, Goldenberger D, Schmidt F, et al. Development and application of two independent real-time PCR assays to detect clinically relevant mucorales species. J Med Microbiol. 2016;65(3):227–234.
   PubMedGoogle Scholar
• Baldin C, S S M S, H H J, et al. PCR-based approach targeting mucorales-specific gene family for diagnosis of mucormycosis. J Clin Microbiol. 2018;56(10):e00746–18.
   PubMed Web of Science ®Google Scholar
• Mercier T, Reynders M, Beuselinck K, et al. Serial detection of circulating mucorales DNA in invasive mucormycosis: a retrospective multicenter evaluation. J Fungi (Basel). 2019;5(4):113.
   Google Scholar
• Gamaletsou MN, Sipsas NV, Roilides E, et al. Rhino-orbital-cerebral mucormycosis. Curr Infect Dis Rep. 2012;14(4):423–434.
   PubMed Web of Science ®Google Scholar
• Koc Z, Koc F, Yerdelen D, et al. Rhino-orbital-cerebral mucormycosis with different cerebral involvements: infarct, hemorrhage, and ophthalmoplegia. Int J Neurosci. 2007;117(12):1677–1690.
   PubMed Web of Science ®Google Scholar
• Hammer MM, Madan R, Hatabu H. Pulmonary mucormycosis: radiologic features at presentation and over time. Am J Roentgenol. 2018;210(4):742–747.
   PubMed Web of Science ®Google Scholar
• Legouge C, Caillot D, Chrétien ML, et al. The reversed halo sign: pathognomonic pattern of pulmonary mucormycosis in leukemic patients with neutropenia? Clin Infect Dis. 2014;58(5):672–678.
   PubMed Web of Science ®Google Scholar
• Chung JH, Godwin JD, Chien JW, et al. Case 160: pulmonary mucormycosis. Radiology. 2010;256(2):667–670.
   PubMed Web of Science ®Google Scholar
• Choo JY, Park CM, Lee HJ, et al. Sequential morphological changes in follow-up CT of pulmonary mucormycosis. Diagn Interv Radiol. 2014;20(1):42–46.
   PubMed Web of Science ®Google Scholar
• Cheng VCC, Chen JHK, Wong SCY, et al. Hospital outbreak of pulmonary and cutaneous zygomycosis due to contaminated linen items from substandard laundry. Clin Infect Dis. 2016;62(6):714–721.
   PubMed Web of Science ®Google Scholar
• Teal LJ, Schultz KM, Weber DJ, et al. Invasive cutaneous rhizopus infections in an immunocompromised patient population associated with hospital laundry carts. Infect Control Hosp Epidemiol. 2016;37(10):1251–1253.
   PubMed Web of Science ®Google Scholar
• Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007;356(4):348–359.
   PubMed Web of Science ®Google Scholar
• Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med. 2007;356(4):335–347.
   PubMed Web of Science ®Google Scholar
• Pagano L, Caira M, Candoni A, et al. Evaluation of the practice of antifungal prophylaxis use in patients with newly diagnosed acute myeloid leukemia: results from the SEIFEM 2010-B registry. Clin Infect Dis. 2012;55(11):1515–1521.
   PubMed Web of Science ®Google Scholar
• Cho SY, Lee DG, Choi SM, et al. Posaconazole for primary antifungal prophylaxis in patients with acute myeloid leukaemia or myelodysplastic syndrome during remission induction chemotherapy: a single-centre retrospective study in Korea and clinical considerations. Mycoses. 2015;58(9):565–571.
   PubMedGoogle Scholar
• Lamoth F, Chung SJ, Damonti L, et al. Changing epidemiology of invasive mold infections in patients receiving azole prophylaxis. Clin Infect Dis. 2017;64(11):1619–1621.
   PubMed Web of Science ®Google Scholar
• Lerolle N, Raffoux E, Socie G, et al. Breakthrough invasive fungal disease in patients receiving posaconazole primary prophylaxis: a 4-year study. Clin Microbiol Infect. 2014;20(11):O952–9.
   PubMed Web of Science ®Google Scholar
• Krishna G, Moton A, Ma L, et al. Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob Agents Chemother. 2009;53(3):958–966.
   PubMed Web of Science ®Google Scholar
• Duarte RF, López-Jiménez J, Cornely OA, et al. Phase 1b study of new posaconazole tablet for prevention of invasive fungal infections in high-risk patients with neutropenia. Antimicrob Agents Chemother. 2014;58(10):5758–5766.
   PubMed Web of Science ®Google Scholar
• Cornely OA, Duarte RF, Haider S, et al. Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease. J Antimicrob Chemother. 2016;71(3):718–726.
   PubMed Web of Science ®Google Scholar
• Chin A, Pergam SA, Fredricks DN, et al. Evaluation of posaconazole serum concentrations from delayed-release tablets in patients at high risk for fungal infections. Antimicrob Agents Chemother. 2017;61(10):e00569–17.
   PubMed Web of Science ®Google Scholar
• Cornely OA, Robertson MN, Haider S, et al. Pharmacokinetics and safety results from the Phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease. J Antimicrob Chemother. 2017;72(12):3406–3413.
   PubMed Web of Science ®Google Scholar
• Jeong W, Haywood P, Shanmuganathan N, et al. Safety, clinical effectiveness and trough plasma concentrations of intravenous posaconazole in patients with haematological malignancies and/or undergoing allogeneic haematopoietic stem cell transplantation: off-trial experience. J Antimicrob Chemother. 2016;71(12):3540–3547.
   PubMed Web of Science ®Google Scholar
• Maertens J, Cornely OA, Ullmann AJ, et al. Phase 1B study of the pharmacokinetics and safety of posaconazole intravenous solution in patients at risk for invasive fungal disease. Antimicrob Agents Chemother. 2014;58(7):3610–3617.
   PubMed Web of Science ®Google Scholar
• Heimann SM, Penack O, Heinz WJ, et al. Intravenous and tablet formulation of posaconazole in antifungal therapy and prophylaxis: A retrospective, non-interventional, multicenter analysis of hematological patients treated in tertiary-care hospitals. Int J Infect Dis. 2019;83:130–138.
   PubMed Web of Science ®Google Scholar
• Gebremariam T, Alkhazraji S, Baldin C, et al. Prophylaxis with Isavuconazole or Posaconazole protects immunosuppressed mice from pulmonary mucormycosis. Antimicrob Agents Chemother. 2017;61(5):e02589–16.
   PubMed Web of Science ®Google Scholar
• Rausch CR, DiPippo AJ, Bose P, et al. Breakthrough fungal infections in patients with leukemia receiving isavuconazole. Clin Infect Dis. 2018;67(10):1610–1613.
   PubMed Web of Science ®Google Scholar
• Cornely OA, Leguay T, Maertens J, et al. Randomized comparison of liposomal amphotericin B versus placebo to prevent invasive mycoses in acute lymphoblastic leukaemia. J Antimicrob Chemother. 2017;72(8):2359–2367.
   PubMed Web of Science ®Google Scholar
• Kontoyiannis DP, Lewis RE. How I treat mucormycosis. Blood. 2011;118(5):1216–1224.
   PubMed Web of Science ®Google Scholar
• Busca A, Marmont F, Locatelli F, et al. Combined antifungal therapy, iron chelation and surgical resection as treatment of hepatic zygomycosis in a patient with haematological malignancy. Mycoses. 2010;53(3):275–278.
   PubMed Web of Science ®Google Scholar
• Cheong HS, Kim SY, Ki HK, et al. Oral mucormycosis in patients with haematologic malignancies in a bone marrow transplant unit. Mycoses. 2017;60(12):836–841.
   PubMed Web of Science ®Google Scholar
• Cornely OA, Arikan-Akdagli S, Dannaoui E, et al. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. Clin Microbiol Infect. 2014;20(Suppl. 3):5–26.
   PubMed Web of Science ®Google Scholar
• Tissot F, Agrawal S, Pagano L, et al. ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. Haematologica. 2017;102(3):433–444.
   PubMed Web of Science ®Google Scholar
• Skiada A, Pagano L, Groll AH, et al. Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) working group on zygomycosis between 2005 and 2007. Clin Microbiol Infect. 2011;17(12):1859–1867.
   PubMed Web of Science ®Google Scholar
• Groll AH, Giri N, Petraitis V, et al. Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. J Infect Dis. 2000;182(1):274–282.
   PubMed Web of Science ®Google Scholar
• Chamilos G, Russell EL, Kontoyiannis DP. Delaying amphotericin B–based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis. 2008;47(4):503–509.
   PubMed Web of Science ®Google Scholar
• Salmanton-Garcıa J, Seidel D, Koehler P, et al. Matched-paired analysis of patients treated for invasive mucormycosis: standard treatment versus posaconazole new formulations (MoveOn). J Antimicrob Chemother. 2019;74(11):3315–3327.
   PubMed Web of Science ®Google Scholar
• Ballester F, Pastor FJ, Guarro J. In vitro activities of combinations of amphotericin B, posaconazole and four other agents against Rhizopus. J Antimicrob Chemother. 2008;61(3):755–757.
   PubMed Web of Science ®Google Scholar
• Rodríguez MM, Calvo E, Serena C, et al. Effects of double and triple combinations of antifungal drugs in a murine model of disseminated infection by Scedosporium prolificans. Antimicrob Agents Chemother. 2009;53(5):2153–2155.
   PubMed Web of Science ®Google Scholar
• Ibrahim AS, Gebremariam T, Fu Y, et al. Combination echinocandin-polyene treatment of murine mucormycosis. Antimicrob Agents Chemother. 2008;52(4):1556–1558.
   PubMed Web of Science ®Google Scholar
• Pagano L, Cornely OA, Busca A, et al. Combined antifungal approach for the treatment of invasive mucormycosis in patients with hematologic diseases: a report from the SEIFEM and FUNGISCOPE registries. Haematologica. 2013;98(10):e127–30.
   PubMed Web of Science ®Google Scholar
• Reed C, Bryant R, Ibrahim AS, et al. Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis. 2008;47(3):364–371.
   PubMed Web of Science ®Google Scholar
• Ibrahim AS, Gebermariam T, Fu Y, et al. The iron chelator deferasirox protects mice from mucormycosis through iron starvation. J Clin Invest. 2007;117(9):2649–2657.
   PubMed Web of Science ®Google Scholar
• Spellberg B, Andes D, Perez M, et al. Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis. Antimicrob Agents Chemother. 2009;53(7):3122–3125.
   PubMed Web of Science ®Google Scholar
• Kara IO, Tasova Y, Uguz A, et al. Mucormycosis-associated fungal infections in patients with haematologic malignancies. Int J Clin Pract. 2009;63(1):134–139.
   PubMed Web of Science ®Google Scholar
• Kontoyiannis DP, Wessel VC, Bodey GP, et al. Zygomycosis in the 1990s in a tertiary-care cancer center. Clin Infect Dis. 2000;30(6):851–856.
   PubMed Web of Science ®Google Scholar
• Grimaldi D, Pradier O, Hotchkiss RS, et al. Nivolumab plus interferon-gamma in the treatment of intractable mucormycosis. Lancet Infect Dis. 2017;17(1):18.
   PubMed Web of Science ®Google Scholar
• Schmidt S, Tramsen L, Schneider A, et al. Immunotherapeutic strategies against mucormycosis in haematopoietic stem cell transplantation. Mycoses. 2014;57(Suppl. 3):8–12.
   PubMedGoogle Scholar